BE-43472D(BE-43472D) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用方式-

作用机制-

治疗领域

肿瘤

在研适应症-

非在研适应症

肿瘤

原研机构

Banyu Pharmaceutical Co. Ltd.

在研机构-

非在研机构-

权益机构-

最高研发阶段无进展临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构/序列

分子式C33H26O9

InChIKeyYQPAMUXTSLWBOC-NRVSKZPNSA-N

CAS号180027-61-6

关联

100 项与 BE-43472D 相关的临床结果

登录后查看更多信息

100 项与 BE-43472D 相关的转化医学

登录后查看更多信息

100 项与 BE-43472D 相关的专利（医药）

登录后查看更多信息

1

项与 BE-43472D 相关的文献（医药）

2006-12-01·Bioorganic & Medicinal Chemistry3区 · 医学

New bisanthraquinone antibiotics and semi-synthetic derivatives with potent activity against clinical Staphylococcus aureus and Enterococcus faecium isolates

3区 · 医学

Article

作者: David C. Rowley ; Kerry L. LaPlante ; Aaron M. Socha

The escalation of antibiotic resistance among Gram-positive pathogens presents increasing treatment challenges and requires the development of innovative therapeutic agents. Here, we present the antimicrobial properties of structurally unusual bisanthraquinone metabolites produced by a marine streptomycete and four semi-synthetic derivatives. Biological activities were measured against clinically derived isolates of vancomycin-resistant Enterococcus faecium (VRE), and methicillin-susceptible, methicillin-resistant, and tetracycline-resistant Staphylococcus aureus (MSSA, MRSA, and TRSA, respectively). The most potent antibiotic displayed MIC(50) values of 0.11, 0.23, and 0.90microM against a panel (n=25 each) of clinical MSSA, MRSA, and VRE, respectively, and was determined to be bactericidal by time-kill analysis.

100 项与 BE-43472D 相关的药物交易

登录后查看更多信息